CD40L-Tri, a novel formulation of recombinant human CD40L that effectively activates B cells

@inproceedings{Naito2012CD40LTriAN,
  title={CD40L-Tri, a novel formulation of recombinant human CD40L that effectively activates B cells},
  author={Masayasu Naito and Ursula Hainz and Ute E. Burkhardt and Buyin Fu and Deborah Ahove and Kristen E. Stevenson and Mohini Rajasagi and Baogong Zhu and Anselmo Alonso and Elizabeth A Witten and Ken-ichi Matsuoka and Donna S Neuberg and Jonathan S Duke-Cohan and Catherine J. Wu and Gordon J Freeman},
  booktitle={Cancer Immunology, Immunotherapy},
  year={2012}
}

• Masayasu Naito, Ursula Hainz, +12 authors Gordon J Freeman
• Published 2012 in Cancer Immunology, Immunotherapy
• DOI:10.1007/s00262-012-1331-4

CD40L has a well-established role in enhancing the immunostimulatory capacity of normal and malignant B cells, but a formulation suitable for clinical use has not been widely available. Like other TNF family members, in vivo and in vitro activity of CD40L requires a homotrimeric configuration, and growing evidence suggests that bioactivity depends on higher-order clustering of CD40. We generated a novel formulation of human recombinant CD40L (CD40L-Tri) in which the CD40L extracellular domain… CONTINUE READING

Save to Library

Create Alert

Cite

View on Springer